Treatment Patterns and Costs Associated with Diffuse Large B|Cell ...

Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell ...

Diffuse large B-cell lymphoma (DLBCL) is typically treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone ...

Treatment and outcomes for patients with relapsed or refractory ...

Diffuse large B-cell lymphoma (DLBCL) is a common and aggressive form of non-Hodgkin lymphoma primarily affecting adults.

Real-World Treatment Patterns, Survival, Health Resource Use, and ...

C83.35 Diffuse large B-cell lymphoma, lymph nodes of ... Keywords. costsdiffuse large B-cell lymphomaelderlyMedicaresurvivaltreatment patterns ...

Medicare Utilization and Cost Trends for CAR T Cell Therapies ...

Chimeric antigen receptor T-cell (CAR T) therapies have transformed the treatment of diffuse large B-cell lymphoma (DLBCL), yet understanding of ...

Transplantation and Cellular Therapy

The use of chimeric antigen receptor (CAR) T-cell therapy after a second relapse of diffuse large B-cell lymphoma. (DLBCL) has shown ...

Burden of Illness and Treatment Patterns in Second-line Large B ...

Key words: health care resource utilization and costs, large B-cell lymphoma, stem cell transplant, treatment pattern, treatment-related adverse events.

Treatment approaches for older and oldest patients with diffuse ...

We characterized real-world treatment patterns in older (65–74 years) and oldest (75–85 years) patients with diffuse large B-cell lymphoma ( ...

Case Study: Medicare Utilization and Cost Trends for CAR-T Cell ...

Case Study: Medicare Utilization and Cost Trends for CAR-T Cell Therapies Across Settings of Care in the Treatment of Diffuse Large B-Cell ...

Real-World Treatment Patterns and Healthcare Costs Among ...

... diffuse large B-cell lymphoma, or unspecified lymphoma. FL-related pharmacy costs were defined as claims for antineoplastic agents used for the treatment of FL.

Real-world treatment pathways of patients with diffuse large B-cell

➢ Not involved in a clinical trial at data collection. • Descriptive statistics were used to describe patient treatment patterns and pathways, statistical ...

B-Cell Non-Hodgkin Lymphoma Treatment (PDQ®) - NCI

... of lymphoproliferative malignancies with differing patterns of behavior and responses to treatment ... treatment of diffuse large B-cell lymphoma.

Diffuse large B-cell lymphoma involving the central nervous system

The prognosis of PCNSL is significantly worse than systemic DLBCL. Although induction therapy achieves remission in approximately 50% of ...

Cost drivers associated with diffuse large B-cell lymphoma (DLBCL ...

From the database, rrDLBCL patients on 2L or 3L of treatment were grouped into respective cohorts. The mean [median] (SD) total medical cost of ...

News & Literature Highlights - DLBCL

Real-world patient characteristics, treatment patterns, and treatment outcomes of patients with diffuse large B-cell lymphoma by line of therapy · 2024 ASCO ...

Cost-effectiveness of Axicabtagene Ciloleucel and Tisagenlecleucel ...

Although CAR T cell therapies have demonstrated improved overall response rates, concerns remain regarding clinical trial designs based on ...

Diffuse Large B-Cell Lymphoma and Related Entities (28.04.2023)

An overview of the abbreviations for all treatment schedules can be found in Table 1. R-CHOP achieves cure in around 70% of patients with DLBCL ...

Biomarkers and novel therapeutic approaches for diffuse large B ...

Despite the great efforts for better treatment options for diffuse large B-cell lymphoma (DLBCL) (most common form of non-Hodgkin lymphoma, NHL) ...

Diffuse Large B-Cell Lymphoma | NEJM

DLBCL, an aggressive cancer, accounts for about 30% of all lymphomas. Empirical combination chemotherapy cures about 65% of patients initially.

a Hong Kong population-based study | Scientific Reports - Nature

Socioeconomic inequalities in treatment and relative survival among patients with diffuse large B-cell lymphoma: a Hong Kong population-based ...

Treatment patterns and predictors of survival after first line therapy in ...

Patients with large B cell lymphoma (LBCL) have a number of choices of front line (1L) therapies; however, relapsed and refractory disease are common, ...